Detalles de la búsqueda
1.
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy.
Nature
; 629(8010): 201-210, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38600376
2.
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.
Mol Cell
; 81(10): 2183-2200.e13, 2021 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019788
3.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med
; 389(4): 335-347, 2023 Jul 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37272512
4.
Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy.
Haematologica
; 109(3): 787-798, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37767564
5.
Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy.
Haematologica
; 2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38268493
6.
Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.
Haematologica
; 2024 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38235519
7.
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 24(7): e293-e311, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37414019
8.
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16).
Br J Haematol
; 202(4): 801-811, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37357593
9.
Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients.
Haematologica
; 2023 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37855027
10.
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells.
Haematologica
; 108(1): 83-97, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35770527
11.
Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.
Eur J Haematol
; 110(2): 168-176, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36321745
12.
Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry.
Intern Med J
; 2023 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38149340
13.
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Intern Med J
; 53(4): 599-609, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36441109
14.
Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma.
Intern Med J
; 53(8): 1469-1477, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37093163
15.
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments.
Nature
; 538(7626): 518-522, 2016 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-27750279
16.
A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation.
Clin Infect Dis
; 73(11): e4269-e4277, 2021 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33175132
17.
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Br J Haematol
; 194(1): 120-131, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34036560
18.
Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome.
Blood
; 134(16): 1346-1350, 2019 10 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31467061
19.
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
Future Oncol
; 17(34): 4797-4812, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34521277
20.
Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study.
Mycoses
; 64(1): 30-34, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32885525